Diligence memo · auto-generated · as of July 2, 2026
Metuchen Pharmaceuticals, LLC
Metuchen Pharmaceuticals, LLC looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Metuchen Pharmaceuticals, LLC operates in Pharmaceuticals, based in MANALAPAN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Metuchen Pharmaceuticals, LLC has raised $3.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.1M on 2019-09-16.
Most recent recorded round closed around 2019-09-16.
Valuation (modeled)modeled
Provath models Metuchen Pharmaceuticals, LLC at approximately $119M (range $2.4M–$935M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.09× the median modeled value of Seed Pharmaceuticals companies in 2019–2021 (49 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 6.8 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 35% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 58% of those peers.
Closest niche peers: Wiesman Capital & Co., LLC, Curzion Pharmaceuticals, Inc., Providence Therapeutics Inc., EnBiotix, Inc., VasoRx, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.